Table 3. Short Summary of Participant Vaccination and Immunology Evaluations.
| Evaluation | Screen (45 Days) | Study Day | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| −84 | −77 | −56 | −14 | 0 | 7 | 14 | 28 | 35 | 42 | 56 | 98 | ||
| BCG administration | x | ||||||||||||
| AERAS-402/placebo administration | x | x | |||||||||||
| Immunology: ICSb, ELISPOT | x | x | x | x | |||||||||
| Leukapheresis | x | xa | |||||||||||
aStudy Day 98 leukapheresis was done any time after the Study Day 56 visit but no later than the Study Day 98 visit. Note: The amount of blood required for this study is within WHO guidelines for blood donation.
bICS was also performed on day 98.